SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has finalized the commercial terms of its agreement with Croda plc following successful testing of the SkinBiotix™ technology. The agreement includes tiered royalties for SkinBioTherapeutics based on global sales revenues from licensed products derived from their partnership. The original agreement, signed in November…
All posts tagged SkinBioTherapeutics
SkinBioTherapeutics has acquired Bio-Tech Solutions for £1.25 million
LONDON: SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announced the acquisition of the entire share capital of Bio-Tech Solutions Ltd (BTS) for a total enterprise consideration of £1.25m payable in cash on closing. BTS is the second acquisition of the Group’s M&A strategy and brings the capabilities of manufacturing and…
SkinBioTherapeutics acquires Dermatonics Limited for £2.93 million
LONDON, UK: SkinBioTherapeutics plc (AIM: SBTX) has entered into an agreement to acquire the issued share capital of Dermatonics Limited, a specialist in innovative topical and dermatological products in the skincare/woundcare space. The initial consideration is £1.68 million plus £1.25 million earn-out over three years, in a cash-free and debt-free acquisition. Completion will take place…